JP2007517543A - ポリマー化合物とその使用法 - Google Patents
ポリマー化合物とその使用法 Download PDFInfo
- Publication number
- JP2007517543A JP2007517543A JP2006541670A JP2006541670A JP2007517543A JP 2007517543 A JP2007517543 A JP 2007517543A JP 2006541670 A JP2006541670 A JP 2006541670A JP 2006541670 A JP2006541670 A JP 2006541670A JP 2007517543 A JP2007517543 A JP 2007517543A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- fiber formation
- polymer
- reactant
- formation inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 title claims abstract 499
- 150000001875 compounds Chemical class 0.000 title claims abstract 218
- 239000003112 inhibitor Substances 0.000 claims abstract 1084
- 230000015572 biosynthetic process Effects 0.000 claims abstract 729
- 239000000835 fiber Substances 0.000 claims abstract 701
- 206010016654 Fibrosis Diseases 0.000 claims abstract 287
- 230000004761 fibrosis Effects 0.000 claims abstract 287
- 239000000203 mixture Substances 0.000 claims abstract 57
- 239000007943 implant Substances 0.000 claims abstract 26
- 238000011282 treatment Methods 0.000 claims abstract 7
- 238000000034 method Methods 0.000 claims 1658
- 239000000376 reactant Substances 0.000 claims 451
- 108010035532 Collagen Proteins 0.000 claims 114
- 102000008186 Collagen Human genes 0.000 claims 114
- 229920001436 collagen Polymers 0.000 claims 114
- 229960005475 antiinfective agent Drugs 0.000 claims 94
- 239000004599 antimicrobial Substances 0.000 claims 94
- 210000001519 tissue Anatomy 0.000 claims 49
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 48
- 239000005557 antagonist Substances 0.000 claims 48
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 48
- 102000004169 proteins and genes Human genes 0.000 claims 47
- 108090000623 proteins and genes Proteins 0.000 claims 47
- 125000003277 amino group Chemical group 0.000 claims 36
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 36
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 36
- 230000002924 anti-infective effect Effects 0.000 claims 32
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 30
- 229920001281 polyalkylene Polymers 0.000 claims 30
- 239000000556 agonist Substances 0.000 claims 29
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 24
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 24
- 108010039918 Polylysine Proteins 0.000 claims 24
- 229940121375 antifungal agent Drugs 0.000 claims 24
- 239000003429 antifungal agent Substances 0.000 claims 24
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 24
- 229940043355 kinase inhibitor Drugs 0.000 claims 24
- 235000014655 lactic acid Nutrition 0.000 claims 24
- 239000004310 lactic acid Substances 0.000 claims 24
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 24
- 229960001237 podophyllotoxin Drugs 0.000 claims 24
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical group COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 24
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 24
- 229920000656 polylysine Polymers 0.000 claims 24
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 19
- 229920001059 synthetic polymer Polymers 0.000 claims 19
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical group N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 18
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 18
- 229940123034 Heat shock protein 90 antagonist Drugs 0.000 claims 18
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 18
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 18
- 230000006870 function Effects 0.000 claims 18
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 18
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 18
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 18
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 18
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 18
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 18
- 238000003786 synthesis reaction Methods 0.000 claims 18
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 18
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 17
- PGEGFAGJACEMIS-UHFFFAOYSA-N carbon dioxide;pyrrolidine-2,5-dione Chemical group O=C=O.O=C1CCC(=O)N1 PGEGFAGJACEMIS-UHFFFAOYSA-N 0.000 claims 16
- 230000008878 coupling Effects 0.000 claims 15
- 238000010168 coupling process Methods 0.000 claims 15
- 238000005859 coupling reaction Methods 0.000 claims 15
- 210000004204 blood vessel Anatomy 0.000 claims 14
- 230000003872 anastomosis Effects 0.000 claims 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 12
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical group FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 claims 12
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 12
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 12
- 108010049003 Fibrinogen Proteins 0.000 claims 12
- 102000008946 Fibrinogen Human genes 0.000 claims 12
- 229940122331 Fibrinogen antagonist Drugs 0.000 claims 12
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 12
- 108010010803 Gelatin Proteins 0.000 claims 12
- 229940118547 Guanylate cyclase stimulant Drugs 0.000 claims 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 12
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical group NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 12
- 229940122255 Microtubule inhibitor Drugs 0.000 claims 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 12
- 229930012538 Paclitaxel Natural products 0.000 claims 12
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 12
- 229920000229 biodegradable polyester Polymers 0.000 claims 12
- 239000004622 biodegradable polyester Substances 0.000 claims 12
- 229920002988 biodegradable polymer Polymers 0.000 claims 12
- 239000004621 biodegradable polymer Substances 0.000 claims 12
- 229940127093 camptothecin Drugs 0.000 claims 12
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 12
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims 12
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 12
- 229960004679 doxorubicin Drugs 0.000 claims 12
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 12
- 229960005420 etoposide Drugs 0.000 claims 12
- 229940012952 fibrinogen Drugs 0.000 claims 12
- 229960002949 fluorouracil Drugs 0.000 claims 12
- 239000004052 folic acid antagonist Substances 0.000 claims 12
- 229920000159 gelatin Polymers 0.000 claims 12
- 239000008273 gelatin Substances 0.000 claims 12
- 235000019322 gelatine Nutrition 0.000 claims 12
- 235000011852 gelatine desserts Nutrition 0.000 claims 12
- 229960001330 hydroxycarbamide Drugs 0.000 claims 12
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 12
- 229960001156 mitoxantrone Drugs 0.000 claims 12
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 12
- 229960001592 paclitaxel Drugs 0.000 claims 12
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 12
- 229920001223 polyethylene glycol Polymers 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 12
- 229960002930 sirolimus Drugs 0.000 claims 12
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 12
- 229960001967 tacrolimus Drugs 0.000 claims 12
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 12
- 150000003573 thiols Chemical class 0.000 claims 12
- 239000003614 peroxisome proliferator Substances 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 108020004414 DNA Proteins 0.000 claims 8
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical group O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 7
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 7
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 7
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 210000002744 extracellular matrix Anatomy 0.000 claims 7
- 210000002950 fibroblast Anatomy 0.000 claims 7
- 230000019305 fibroblast migration Effects 0.000 claims 7
- 230000035755 proliferation Effects 0.000 claims 7
- 230000008929 regeneration Effects 0.000 claims 7
- 238000011069 regeneration method Methods 0.000 claims 7
- 230000007838 tissue remodeling Effects 0.000 claims 7
- DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical group CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 claims 6
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 claims 6
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 6
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 6
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 6
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 6
- 239000005541 ACE inhibitor Substances 0.000 claims 6
- 102000055025 Adenosine deaminases Human genes 0.000 claims 6
- 108010088751 Albumins Proteins 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 6
- 229940122195 Alpha2 integrin antagonist Drugs 0.000 claims 6
- 229940086440 Angiotensin I converting enzyme inhibitor Drugs 0.000 claims 6
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 6
- 102000000412 Annexin Human genes 0.000 claims 6
- 108050008874 Annexin Proteins 0.000 claims 6
- 108010039627 Aprotinin Proteins 0.000 claims 6
- 229940122361 Bisphosphonate Drugs 0.000 claims 6
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 6
- 229940123003 Cathepsin inhibitor Drugs 0.000 claims 6
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 6
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 6
- 108020005124 DNA Adducts Proteins 0.000 claims 6
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 6
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 6
- 229940126161 DNA alkylating agent Drugs 0.000 claims 6
- 239000012624 DNA alkylating agent Substances 0.000 claims 6
- 230000006820 DNA synthesis Effects 0.000 claims 6
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 6
- 229940122858 Elastase inhibitor Drugs 0.000 claims 6
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 6
- 229940122586 Enkephalinase inhibitor Drugs 0.000 claims 6
- 102400001368 Epidermal growth factor Human genes 0.000 claims 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims 6
- 102100029951 Estrogen receptor beta Human genes 0.000 claims 6
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 6
- 108010054218 Factor VIII Proteins 0.000 claims 6
- 102000001690 Factor VIII Human genes 0.000 claims 6
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 6
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 6
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 6
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 6
- 229940122296 IKK2 inhibitor Drugs 0.000 claims 6
- 108010087227 IMP Dehydrogenase Proteins 0.000 claims 6
- 102000006674 IMP dehydrogenase Human genes 0.000 claims 6
- 229940122355 Insulin sensitizer Drugs 0.000 claims 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims 6
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims 6
- 108010002352 Interleukin-1 Proteins 0.000 claims 6
- 108090000978 Interleukin-4 Proteins 0.000 claims 6
- 229940123313 MCP-1 antagonist Drugs 0.000 claims 6
- 229940124761 MMP inhibitor Drugs 0.000 claims 6
- 102000029749 Microtubule Human genes 0.000 claims 6
- 108091022875 Microtubule Proteins 0.000 claims 6
- 229930192392 Mitomycin Natural products 0.000 claims 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 6
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical group C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 claims 6
- 229940123134 Nitric oxide inhibitor Drugs 0.000 claims 6
- 229940121682 Osteoclast inhibitor Drugs 0.000 claims 6
- 108091008606 PDGF receptors Proteins 0.000 claims 6
- 229940126033 PPAR agonist Drugs 0.000 claims 6
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 6
- 229940121927 Phospholipase A1 inhibitor Drugs 0.000 claims 6
- 102000015439 Phospholipases Human genes 0.000 claims 6
- 108010064785 Phospholipases Proteins 0.000 claims 6
- 102000013566 Plasminogen Human genes 0.000 claims 6
- 108010051456 Plasminogen Proteins 0.000 claims 6
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 6
- 229940120646 Platelet-derived growth factor receptor kinase inhibitor Drugs 0.000 claims 6
- 229940123924 Protein kinase C inhibitor Drugs 0.000 claims 6
- 229940123752 RNA synthesis inhibitor Drugs 0.000 claims 6
- 229940122756 Retinoic acid receptor antagonist Drugs 0.000 claims 6
- 108091028664 Ribonucleotide Proteins 0.000 claims 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 6
- 229940123237 Taxane Drugs 0.000 claims 6
- 108090000190 Thrombin Proteins 0.000 claims 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 6
- 229940122435 VCAM-1 antagonist Drugs 0.000 claims 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 6
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 claims 6
- 229940122803 Vinca alkaloid Drugs 0.000 claims 6
- 108010031318 Vitronectin Proteins 0.000 claims 6
- 102100035140 Vitronectin Human genes 0.000 claims 6
- LVBMFPUTQOHXQE-UHFFFAOYSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-(3-aminopropylamino)butyl]carbamate Chemical group NCCCNCCCCNC(=O)OCC(=O)NCCCCCCN=C(N)N LVBMFPUTQOHXQE-UHFFFAOYSA-N 0.000 claims 6
- 238000009825 accumulation Methods 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 125000005227 alkyl sulfonate group Chemical group 0.000 claims 6
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 6
- 239000002260 anti-inflammatory agent Substances 0.000 claims 6
- 230000000340 anti-metabolite Effects 0.000 claims 6
- 239000003146 anticoagulant agent Substances 0.000 claims 6
- 229940100197 antimetabolite Drugs 0.000 claims 6
- 239000002256 antimetabolite Substances 0.000 claims 6
- 229960004676 antithrombotic agent Drugs 0.000 claims 6
- 230000006907 apoptotic process Effects 0.000 claims 6
- 229960004405 aprotinin Drugs 0.000 claims 6
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical group CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims 6
- 229960005207 auranofin Drugs 0.000 claims 6
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 6
- 229940092705 beclomethasone Drugs 0.000 claims 6
- 230000003115 biocidal effect Effects 0.000 claims 6
- 150000004663 bisphosphonates Chemical group 0.000 claims 6
- 239000011612 calcitriol Substances 0.000 claims 6
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 6
- 159000000007 calcium salts Chemical class 0.000 claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 6
- 235000014633 carbohydrates Nutrition 0.000 claims 6
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 6
- 229960004316 cisplatin Drugs 0.000 claims 6
- 239000003086 colorant Substances 0.000 claims 6
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 6
- 230000001086 cytosolic effect Effects 0.000 claims 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 6
- 229960003957 dexamethasone Drugs 0.000 claims 6
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical group OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 claims 6
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 6
- 239000003602 elastase inhibitor Substances 0.000 claims 6
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 6
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 6
- 229940116977 epidermal growth factor Drugs 0.000 claims 6
- 102000015694 estrogen receptors Human genes 0.000 claims 6
- 108010038795 estrogen receptors Proteins 0.000 claims 6
- 229960005167 everolimus Drugs 0.000 claims 6
- 229960000301 factor viii Drugs 0.000 claims 6
- 229940126864 fibroblast growth factor Drugs 0.000 claims 6
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical group N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 6
- 239000003862 glucocorticoid Substances 0.000 claims 6
- 229960002706 gusperimus Drugs 0.000 claims 6
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical group NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims 6
- 229960001340 histamine Drugs 0.000 claims 6
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 6
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 6
- 229920002674 hyaluronan Polymers 0.000 claims 6
- 229960003160 hyaluronic acid Drugs 0.000 claims 6
- 230000007062 hydrolysis Effects 0.000 claims 6
- 238000006460 hydrolysis reaction Methods 0.000 claims 6
- 230000000774 hypoallergenic effect Effects 0.000 claims 6
- 239000002955 immunomodulating agent Substances 0.000 claims 6
- 229940121354 immunomodulator Drugs 0.000 claims 6
- 230000002584 immunomodulator Effects 0.000 claims 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims 6
- 230000001861 immunosuppressant effect Effects 0.000 claims 6
- 239000003018 immunosuppressive agent Substances 0.000 claims 6
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 6
- 239000012948 isocyanate Substances 0.000 claims 6
- 150000002513 isocyanates Chemical class 0.000 claims 6
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 6
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 6
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 6
- 229960004961 mechlorethamine Drugs 0.000 claims 6
- 229960000485 methotrexate Drugs 0.000 claims 6
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 6
- 210000004688 microtubule Anatomy 0.000 claims 6
- 229960004857 mitomycin Drugs 0.000 claims 6
- 229960000951 mycophenolic acid Drugs 0.000 claims 6
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical group OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 6
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 6
- 239000002740 neurokinin 3 receptor antagonist Substances 0.000 claims 6
- 229960003966 nicotinamide Drugs 0.000 claims 6
- 235000005152 nicotinamide Nutrition 0.000 claims 6
- 239000011570 nicotinamide Substances 0.000 claims 6
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical group NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 6
- 230000000269 nucleophilic effect Effects 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 6
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 6
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical group C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 6
- 229960005330 pimecrolimus Drugs 0.000 claims 6
- 229910052697 platinum Inorganic materials 0.000 claims 6
- 150000003058 platinum compounds Chemical group 0.000 claims 6
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 6
- 239000003881 protein kinase C inhibitor Substances 0.000 claims 6
- 239000003909 protein kinase inhibitor Substances 0.000 claims 6
- 238000001243 protein synthesis Methods 0.000 claims 6
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 6
- 230000006824 pyrimidine synthesis Effects 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 229940044551 receptor antagonist Drugs 0.000 claims 6
- 239000002464 receptor antagonist Substances 0.000 claims 6
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 6
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 6
- 239000002336 ribonucleotide Substances 0.000 claims 6
- 125000002652 ribonucleotide group Chemical group 0.000 claims 6
- 239000011435 rock Substances 0.000 claims 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 6
- 229960002855 simvastatin Drugs 0.000 claims 6
- 150000003431 steroids Chemical class 0.000 claims 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 6
- 229960004072 thrombin Drugs 0.000 claims 6
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 6
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 6
- 230000014616 translation Effects 0.000 claims 6
- 229950007229 tresperimus Drugs 0.000 claims 6
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 6
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 6
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 6
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical group C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 6
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical group N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 6
- 229950009819 zotarolimus Drugs 0.000 claims 6
- 230000005778 DNA damage Effects 0.000 claims 5
- 231100000277 DNA damage Toxicity 0.000 claims 5
- 102000006795 dihydrofolate reductase activity proteins Human genes 0.000 claims 5
- 108040000939 dihydrofolate reductase activity proteins Proteins 0.000 claims 5
- 229910052751 metal Inorganic materials 0.000 claims 5
- 239000002184 metal Substances 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 5
- 108010047303 von Willebrand Factor Proteins 0.000 claims 5
- 102100036537 von Willebrand factor Human genes 0.000 claims 5
- 229960001134 von willebrand factor Drugs 0.000 claims 5
- 230000002112 DNA intercalation Effects 0.000 claims 4
- 239000002473 artificial blood Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
- 210000000613 ear canal Anatomy 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
- 238000009423 ventilation Methods 0.000 claims 3
- 210000001367 artery Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 210000003462 vein Anatomy 0.000 claims 2
- 239000012625 DNA intercalator Substances 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 230000003881 arterial anastomosis Effects 0.000 claims 1
- 239000000560 biocompatible material Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000004891 communication Methods 0.000 claims 1
- 238000013461 design Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000000959 ear middle Anatomy 0.000 claims 1
- 239000013536 elastomeric material Substances 0.000 claims 1
- 210000002388 eustachian tube Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 229910001092 metal group alloy Inorganic materials 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 210000001631 vena cava inferior Anatomy 0.000 claims 1
- 230000003878 venous anastomosis Effects 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 208000002260 Keloid Diseases 0.000 abstract 1
- 208000031737 Tissue Adhesions Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000001117 keloid Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52390803P | 2003-11-20 | 2003-11-20 | |
| US52522603P | 2003-11-24 | 2003-11-24 | |
| US52654103P | 2003-12-03 | 2003-12-03 | |
| US56656904P | 2004-04-28 | 2004-04-28 | |
| US58686104P | 2004-07-09 | 2004-07-09 | |
| US61107704P | 2004-09-17 | 2004-09-17 | |
| US10/986,231 US20050181977A1 (en) | 2003-11-10 | 2004-11-10 | Medical implants and anti-scarring agents |
| PCT/US2004/039389 WO2005051452A2 (en) | 2003-11-20 | 2004-11-22 | Polymer compositions and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517543A true JP2007517543A (ja) | 2007-07-05 |
| JP2007517543A5 JP2007517543A5 (https=) | 2008-01-17 |
Family
ID=34637499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541670A Pending JP2007517543A (ja) | 2003-11-20 | 2004-11-22 | ポリマー化合物とその使用法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1684819A2 (https=) |
| JP (1) | JP2007517543A (https=) |
| AU (1) | AU2004293071A1 (https=) |
| CA (1) | CA2536181A1 (https=) |
| IL (1) | IL174641A0 (https=) |
| WO (2) | WO2005051452A2 (https=) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007135965A (ja) * | 2005-11-21 | 2007-06-07 | Tohoku Univ | 体内留置多機能ステントおよびその製造方法 |
| JP2011528275A (ja) * | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ，インク． | 薬物送達医療デバイス |
| JP2012500087A (ja) * | 2008-08-19 | 2012-01-05 | ウォーソー・オーソペディック・インコーポレーテッド | 着色剤を含む骨形成組成物 |
| JP2013063322A (ja) * | 2006-11-06 | 2013-04-11 | Tyrx Inc | 埋込型医療機器のための吸収性パウチ |
| US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
| JP2016518485A (ja) * | 2013-04-10 | 2016-06-23 | ザ ユニヴァーシティー オブ メルボルン | 再生医学用及び組織工学用生分解性ネットワークポリマー |
| KR20200010567A (ko) * | 2011-10-28 | 2020-01-30 | 백스터 인터내셔널 인코포레이티드 | 뼈 지혈용 비-수성 조성물, 그의 사용 방법 및 제조 방법 |
| JP7691565B1 (ja) * | 2024-06-10 | 2025-06-11 | 真由美 大石 | 生体組織の瘢痕化を抑制するための創傷用足場材 |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8163726B2 (en) | 2002-09-18 | 2012-04-24 | University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
| CA2539324A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| WO2005049105A2 (en) * | 2003-11-10 | 2005-06-02 | Angiotech International Ag | Medical implants and anti-scarring agents |
| JP4974903B2 (ja) | 2005-02-09 | 2012-07-11 | 参天製薬株式会社 | 疾患または状態を処置するための液体処方物 |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| US20100040666A1 (en) * | 2005-06-24 | 2010-02-18 | Hiroshi Azuma | Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent |
| WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| PL2001466T3 (pl) | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń |
| EP3047860B1 (en) | 2006-07-20 | 2024-08-28 | OrbusNeich Medical Pte. Ltd. | Bioabsorbable polymeric composition for a medical device |
| US8691321B2 (en) | 2006-10-20 | 2014-04-08 | Orbusneich Medical, Inc. | Bioabsorbable polymeric composition and medical device background |
| US7959942B2 (en) | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
| US7801624B1 (en) | 2007-01-16 | 2010-09-21 | Pacesetter, Inc. | Reduced perforation distal tip for an implantable cardiac electrotherapy lead |
| US9629571B2 (en) | 2007-03-08 | 2017-04-25 | Sync-Rx, Ltd. | Co-use of endoluminal data and extraluminal imaging |
| JP5639764B2 (ja) | 2007-03-08 | 2014-12-10 | シンク−アールエックス，リミティド | 運動する器官と共に使用するイメージング及びツール |
| WO2014002095A2 (en) | 2012-06-26 | 2014-01-03 | Sync-Rx, Ltd. | Flow-related image processing in luminal organs |
| US8542900B2 (en) | 2007-03-08 | 2013-09-24 | Sync-Rx Ltd. | Automatic reduction of interfering elements from an image stream of a moving organ |
| US9375164B2 (en) | 2007-03-08 | 2016-06-28 | Sync-Rx, Ltd. | Co-use of endoluminal data and extraluminal imaging |
| US11064964B2 (en) | 2007-03-08 | 2021-07-20 | Sync-Rx, Ltd | Determining a characteristic of a lumen by measuring velocity of a contrast agent |
| US10716528B2 (en) | 2007-03-08 | 2020-07-21 | Sync-Rx, Ltd. | Automatic display of previously-acquired endoluminal images |
| US9968256B2 (en) | 2007-03-08 | 2018-05-15 | Sync-Rx Ltd. | Automatic identification of a tool |
| US11197651B2 (en) | 2007-03-08 | 2021-12-14 | Sync-Rx, Ltd. | Identification and presentation of device-to-vessel relative motion |
| US8455459B2 (en) | 2007-08-02 | 2013-06-04 | Medicis Pharmaceutical Corporation | Method of applying an injectable filler |
| ES2450391T3 (es) | 2008-06-19 | 2014-03-24 | Sync-Rx, Ltd. | Avance progresivo de un instrumento médico |
| US9144394B2 (en) | 2008-11-18 | 2015-09-29 | Sync-Rx, Ltd. | Apparatus and methods for determining a plurality of local calibration factors for an image |
| US10362962B2 (en) | 2008-11-18 | 2019-07-30 | Synx-Rx, Ltd. | Accounting for skipped imaging locations during movement of an endoluminal imaging probe |
| US9095313B2 (en) | 2008-11-18 | 2015-08-04 | Sync-Rx, Ltd. | Accounting for non-uniform longitudinal motion during movement of an endoluminal imaging probe |
| US9974509B2 (en) | 2008-11-18 | 2018-05-22 | Sync-Rx Ltd. | Image super enhancement |
| US9101286B2 (en) | 2008-11-18 | 2015-08-11 | Sync-Rx, Ltd. | Apparatus and methods for determining a dimension of a portion of a stack of endoluminal data points |
| US8855744B2 (en) | 2008-11-18 | 2014-10-07 | Sync-Rx, Ltd. | Displaying a device within an endoluminal image stack |
| US11064903B2 (en) | 2008-11-18 | 2021-07-20 | Sync-Rx, Ltd | Apparatus and methods for mapping a sequence of images to a roadmap image |
| HUP1000385A2 (en) | 2010-07-21 | 2012-01-30 | Medicontur Orvostechnikai Kft | Alkane diol derivatives preparation thereof and based on them |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| ES2537411T3 (es) | 2011-04-20 | 2015-06-08 | Carbylan Therapeutics, Inc. | Composiciones formadoras de gel in situ |
| EP2723231A4 (en) | 2011-06-23 | 2015-02-25 | Sync Rx Ltd | LUMINAL BACKGROUND CLEANING |
| WO2013011511A1 (en) | 2011-07-18 | 2013-01-24 | Mor Research Applications Ltd. | A device for adjusting the intraocular pressure |
| JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11096781B2 (en) | 2016-08-01 | 2021-08-24 | Edwards Lifesciences Corporation | Prosthetic heart valve |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| CN108498905B (zh) * | 2018-04-03 | 2024-08-06 | 广州迈普再生医学科技股份有限公司 | 用于双联混合注射器的腔镜型喷头及腔镜型双联混合注射器 |
| WO2019094635A1 (en) | 2017-11-09 | 2019-05-16 | 11 Health and Technologies Inc. | Ostomy monitoring system and method |
| WO2020030486A1 (en) * | 2018-08-09 | 2020-02-13 | Gambro Lundia Ab | Method for detection of flow obstruction in an extracorporeal circuit, apparatus and computer program |
| USD893514S1 (en) | 2018-11-08 | 2020-08-18 | 11 Health And Technologies Limited | Display screen or portion thereof with graphical user interface |
| US20200254103A1 (en) * | 2019-02-11 | 2020-08-13 | John Mee | Method for treating neurological conditions and improving human cognition |
| ES2987079T3 (es) | 2020-08-24 | 2024-11-13 | Edwards Lifesciences Corp | Sistemas para alinear una comisura de una válvula cardiaca protésica con una comisura de una válvula nativa |
| JP2023545504A (ja) | 2020-10-15 | 2023-10-30 | コンバテック・テクノロジーズ・インコーポレイテッド | オストミーシステムおよび方法 |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| CN113281317B (zh) * | 2021-05-14 | 2022-04-29 | 北京指真生物科技有限公司 | 一种含有花菁类化合物的编码微球及其制备方法和应用 |
| US12152699B2 (en) | 2022-02-28 | 2024-11-26 | Terumo Bct, Inc. | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| CN115382028A (zh) * | 2022-09-19 | 2022-11-25 | 郑州大学第一附属医院 | 一种可降解吻合器材料及其制备方法和应用 |
| WO2024159015A1 (en) * | 2023-01-25 | 2024-08-02 | North Carolina State University | Compositions and methods relating to inhalable therapeutic compositions |
| CN118903564B (zh) * | 2024-09-02 | 2025-11-04 | 嘉兴睿清医疗科技有限公司 | 一种羟基磷灰石复合聚酯微球及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087563A2 (en) * | 2001-05-01 | 2002-11-07 | Angiotech Pharmaceuticals Inc. | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions |
| JP2003520830A (ja) * | 2000-01-25 | 2003-07-08 | エドワーズ ライフサイエンシーズ コーポレイション | 再狭窄および吻合内膜過形成処置のための送達系 |
| WO2003092741A1 (en) * | 2002-05-03 | 2003-11-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
-
2004
- 2004-11-22 EP EP04816983A patent/EP1684819A2/en not_active Withdrawn
- 2004-11-22 AU AU2004293071A patent/AU2004293071A1/en not_active Abandoned
- 2004-11-22 JP JP2006541670A patent/JP2007517543A/ja active Pending
- 2004-11-22 WO PCT/US2004/039389 patent/WO2005051452A2/en not_active Ceased
- 2004-11-22 WO PCT/US2004/039491 patent/WO2005051316A2/en not_active Ceased
- 2004-11-22 CA CA002536181A patent/CA2536181A1/en not_active Abandoned
-
2006
- 2006-03-30 IL IL174641A patent/IL174641A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003520830A (ja) * | 2000-01-25 | 2003-07-08 | エドワーズ ライフサイエンシーズ コーポレイション | 再狭窄および吻合内膜過形成処置のための送達系 |
| WO2002087563A2 (en) * | 2001-05-01 | 2002-11-07 | Angiotech Pharmaceuticals Inc. | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions |
| WO2003092741A1 (en) * | 2002-05-03 | 2003-11-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007135965A (ja) * | 2005-11-21 | 2007-06-07 | Tohoku Univ | 体内留置多機能ステントおよびその製造方法 |
| JP2013063322A (ja) * | 2006-11-06 | 2013-04-11 | Tyrx Inc | 埋込型医療機器のための吸収性パウチ |
| US9023114B2 (en) | 2006-11-06 | 2015-05-05 | Tyrx, Inc. | Resorbable pouches for implantable medical devices |
| JP2011528275A (ja) * | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ，インク． | 薬物送達医療デバイス |
| JP2012500087A (ja) * | 2008-08-19 | 2012-01-05 | ウォーソー・オーソペディック・インコーポレーテッド | 着色剤を含む骨形成組成物 |
| KR20200010567A (ko) * | 2011-10-28 | 2020-01-30 | 백스터 인터내셔널 인코포레이티드 | 뼈 지혈용 비-수성 조성물, 그의 사용 방법 및 제조 방법 |
| KR102184970B1 (ko) * | 2011-10-28 | 2020-12-03 | 백스터 인터내셔널 인코포레이티드 | 뼈 지혈용 비-수성 조성물, 그의 사용 방법 및 제조 방법 |
| JP2016518485A (ja) * | 2013-04-10 | 2016-06-23 | ザ ユニヴァーシティー オブ メルボルン | 再生医学用及び組織工学用生分解性ネットワークポリマー |
| US10179834B2 (en) | 2013-04-10 | 2019-01-15 | The University Of Melbourne | Biodegradable network polymers for regenerative medicine and tissue engineering |
| JP7691565B1 (ja) * | 2024-06-10 | 2025-06-11 | 真由美 大石 | 生体組織の瘢痕化を抑制するための創傷用足場材 |
| WO2025258414A1 (ja) * | 2024-06-10 | 2025-12-18 | 真由美 大石 | 生体組織の瘢痕化を抑制するための創傷用足場材 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004293071A1 (en) | 2005-06-09 |
| EP1684819A2 (en) | 2006-08-02 |
| WO2005051316A2 (en) | 2005-06-09 |
| CA2536181A1 (en) | 2005-06-09 |
| WO2005051316A3 (en) | 2010-01-28 |
| WO2005051452A2 (en) | 2005-06-09 |
| IL174641A0 (en) | 2006-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050175703A1 (en) | Polymer compositions and methods for their use | |
| JP2007517543A (ja) | ポリマー化合物とその使用法 | |
| CN101420991A (zh) | 聚合物组合物及其使用方法 | |
| US20050177225A1 (en) | Medical implants and anti-scarring agents | |
| KR100974733B1 (ko) | 가교된 생합성물질을 형성하기 위한 조성물 및 시스템, 및이와 관련된 제조 및 사용 방법 | |
| US20050175664A1 (en) | Implantable sensors and implantable pumps and anti-scarring agents | |
| CN101094613A (zh) | 医用植入物和抗瘢痕形成剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110225 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110728 |